The Comfort Trap of Indian Pharma

The global pharmaceutical industry is no longer a linear value chain. It is rapidly becoming a bipolar ecosystem anchored by the United States and China. The US continues to dominate breakthrough innovation and capital formation, while China is integrating R&D, manufacturing, and market scale into a powerful, state-backed engine. In this emerging order, the “middle layer” is thinning out. Companies and countries reliant on cost arbitrage or incremental generics are increasingly exposed.For Indian pharma, this is a moment of strategic clarity. The question is no longer about incremental upgrades to the generics model, but about repositioning in a polarized world moving into biologics, building integrated capabilities, and leveraging regulatory trust as a global differentiator. For investors and CXOs alike, the next decade will reward those who shift from volume-driven growth to capability-led value creation.Listen and share. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com